P
0.552
0.15 (36.49%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | PLUS THERAPEUTICS, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-0.4
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.38 |
|
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.02% |
| 机构持股比例 | 2.50% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tradewinds Capital Management, Llc | 30 Jun 2025 | 200 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 5.00 (D. Boral Capital, 806.29%) | 购买 |
| 中 | 4.00 (625.03%) | |
| 低 | 3.00 (Maxim Group, 443.77%) | 购买 |
| 平均值 | 4.00 (625.03%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 0.550 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 25 Sep 2025 | 5.00 (806.29%) | 购买 | 0.560 |
| 22 Sep 2025 | 5.00 (806.29%) | 购买 | 0.420 | |
| Maxim Group | 18 Aug 2025 | 3.00 (443.77%) | 购买 | 0.540 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合